Gilead Sciences
Gilead Sciences is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Gilead Sciences.
Gilead Sciences is a company.
Key people at Gilead Sciences.
Key people at Gilead Sciences.
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines targeting unmet medical needs in life-threatening diseases, particularly viral infections like HIV, hepatitis C, and influenza.[3][4][5] It serves patients worldwide through therapies such as Vistide (1996, for cytomegalovirus retinitis in AIDS patients), Viread (2001, HIV treatment), Tamiflu, Sovaldi (2013, hepatitis C cure advancement), and single-tablet HIV regimens like Stribild (2011), transforming care for millions while expanding into cell therapy via the 2017 Kite Pharma acquisition.[1][3][4] With strong growth from its 1992 IPO—raising $86 million—and a shift from biotech startup to global pharma leader, Gilead now operates in over 20 countries, employing thousands and addressing public health crises like HIV epidemics.[2][4]
Gilead Sciences was founded on June 22, 1987, as Oligogen by Michael L. Riordan, M.D., a 29-year-old physician inspired by the biblical "balm of Gilead," the ancient Middle East's first known pharmaceutical, to target viral diseases especially HIV and STDs using antisense oligonucleotides—small DNA strands to block disease-triggering genetic messages.[1][2][3][4] Riordan raised $2 million in venture capital the next year, relocating to Foster City, California, and broadening research to antivirals, cardiovascular, and cancer drugs before pivoting fully to small-molecule antivirals by 1990 and exclusively to antivirals in 2002.[1][3][4] Early traction came with its 1992 Nasdaq IPO (ticker: GILD), generating $86.25 million, FDA approval of Vistide in 1996, acquisitions like NeXstar (1999) and Triangle Pharmaceuticals (2002), and Viread's 2001 HIV approval, marking its evolution from speculative biotech to pharmaceutical powerhouse.[1][2][3][4]
Gilead rides the wave of antiviral and gene therapy revolutions, capitalizing on HIV/AIDS crises in the 1980s-90s and hepatitis C epidemics, where timing aligned with nucleotide tech licensing and FDA approvals amid urgent unmet needs.[1][3][4] Market forces like rising viral disease burdens, regulatory fast-tracks for antivirals, and public health demands (e.g., PrEP for prevention) propelled its growth, despite pricing scrutiny on drugs like Sovaldi and Truvada.[3] It influences biotech by modeling acquisition-fueled scaling—evolving from startup to pharma giant—and advancing cures that reshaped HIV from fatal to manageable, while entering cell therapy to shape oncology and immunotherapy ecosystems.[3][4][6]
Gilead's next phase builds on its antiviral dominance through cell therapy expansion (post-Kite) and community programs like HIV Age Positively and HepConnect, targeting oncology, inflammation, and emerging viruses.[4] Trends like personalized medicine, gene editing synergies, and global health equity will shape it, potentially amplifying influence amid pricing pressures and biosimilar competition. As a biopharma trailblazer born from one visionary's bet on viral cures, Gilead remains poised to deliver hope against evolving public health threats.[3][4][6]
